Bayer’s eliapixant hits the right notes in PAGANINI cough studyBayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it Share XBayer’s eliapixant hits the right notes in PAGANINI cough studyhttps://pharmaphorum.com/news/bayers-eliapixant-hits-the-right-notes-in-paganini-cough-study/
Novartis says trials back Beovu safety in diabetic eye diseaseThere is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to Share XNovartis says trials back Beovu safety in diabetic eye diseasehttps://pharmaphorum.com/news/novartis-says-trials-back-beovu-safety-in-diabetic-eye-disease/
Bayer bolsters R&D platform with $2bn Vividion takeoverBayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will Share XBayer bolsters R&D platform with $2bn Vividion takeoverhttps://pharmaphorum.com/news/bayer-bolsters-rd-platform-with-2bn-vividion-takeover/
Chasing Merck & Co, Bayer builds case for cough drug eliapixantBayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase Share XChasing Merck & Co, Bayer builds case for cough drug eliapixanthttps://pharmaphorum.com/news/chasing-merck-bayer-builds-case-for-cough-drug-eliapixant/
FDA starts review of Roche’s eye disease drug, setting up 2022 verdictThe FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, Share XFDA starts review of Roche’s eye disease drug, setting up 2022 verdicthttps://pharmaphorum.com/news/fda-starts-review-of-roches-eye-disease-drug-setting-up-2022-verdict/
FDA gives speedy review to Bayer’s Parkinson’s stem cell therapyBayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based Share XFDA gives speedy review to Bayer’s Parkinson’s stem cell therapyhttps://pharmaphorum.com/news/fda-gives-speedy-review-to-bayers-parkinsons-stem-cell-therapy/
Bayer’s finerenone gets FDA nod for diabetic kidney diseaseBayer’s big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in Share XBayer’s finerenone gets FDA nod for diabetic kidney diseasehttps://pharmaphorum.com/news/bayers-finerenone-gets-fda-nod-for-diabetic-kidney-disease/
Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinicBayer subsidiary BlueRock Therapeutics has dosed the first Parkinson’s disease patient in a phase 1 trial of its Share XBayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinichttps://pharmaphorum.com/news/bayers-two-pronged-cell-gene-therapy-assault-on-parkinsons-enters-clinic/
Bayer props up sagging radionuclide business with Noria acquisitionBayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide Share XBayer props up sagging radionuclide business with Noria acquisitionhttps://pharmaphorum.com/news/bayer-props-up-sagging-radionuclide-business-with-noria-acquisition/
